What is Histogen?
Histogen Inc. is a clinical-stage therapeutics company dedicated to pioneering restorative treatments that harness the body's innate capacity for repair and maintenance of biological functions. The company's proprietary technology leverages cell conditioned media and extracellular matrix materials derived from hypoxia-induced multipotent cells. This advanced, reproducible manufacturing process is designed to deliver targeted solutions for a wide spectrum of therapeutic applications, including joint cartilage regeneration, spinal disk repair, and other soft tissue repair needs.
How much funding has Histogen raised?
Histogen has raised a total of $37.3M across 6 funding rounds:
Private Equity
$9.5M
Private Equity
$6M
Debt
$350K
Share Placement
$10M
Stock Offering
$6.5M
Share Placement
$5M
Private Equity (2007): $9.5M, investors not publicly disclosed
Private Equity (2016): $6M led by Huapont Life Sciences Co.
Debt (2020): $350K supported by PPP
Share Placement (2020): $10M, investors not publicly disclosed
Stock Issuance/Offering (2021): $6.5M, investors not publicly disclosed
Share Placement (2022): $5M, investors not publicly disclosed
Key Investors in Histogen
Huapont Life Sciences Co.
Huapont Life Sciences Co. is a prominent pharmaceutical manufacturer specializing in a diverse range of medical products, including dermatological, respiratory, and anti-tumor treatments. Their involvement suggests a strategic interest in Histogen's therapeutic applications and potential for market expansion.
What's next for Histogen?
With its recent major strategic investment, Histogen is poised to accelerate its clinical development pipeline and expand its therapeutic reach. The company's focus on restorative therapeutics, utilizing a unique cell-based technology, suggests a strategic move towards addressing unmet medical needs in regenerative medicine. Future endeavors will likely involve advancing its lead candidates through clinical trials and potentially exploring new indications for its platform technology, aiming to solidify its position in the competitive biopharmaceutical landscape.
See full Histogen company page
